Office evaluation and management of bladder neoplasms

M. J. Young, M. S. Soloway

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Transitional cell carcinoma is the predominant bladder neoplasm. These tumors are heterogeneous, and the risk of recurrence and progression should guide further management. When this approach is used, patients at lower risk avoid the morbidity and expense of unnecessary interventions and tests, whereas higher-risk patients are treated more aggressively. Cystoscopy and IVP remain the standard initial evaluation for patients suspected of having a bladder neoplasm. Intravesical chemotherapy and immunotherapy can be administered safely in the office to reduce disease recurrence when appropriate. The advent of lasers has permitted fulgaration of low-grade neoplasms in the office with local anesthesia. Surveillance of patients with superficial disease is still largely dependent on office-based cystoscopy. Tumor markers for the identification of recurrent disease are being investigated and may prove useful to reduce the number of negative cystoscopic evaluations performed for surveillance. Patients postcystectomy are followed up with attention to detection of recurrent disease in remnant urothelium, metastatic disease, and metabolic and nutritional disturbances, which may result from urinary diversion.

Original languageEnglish (US)
Pages (from-to)603-611
Number of pages9
JournalUrologic Clinics of North America
Issue number4
StatePublished - Jan 1 1998

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Office evaluation and management of bladder neoplasms'. Together they form a unique fingerprint.

Cite this